Product information and disease descriptionProduct description
Phase of product development
16 evidence topics · 12 sources
Summary: development and regulatory status
- Regulatory status: The company states that it has no products approved for sale and has not generated any product sales. The FDA designated Descartes-08 an orphan drug for the treatment of myasthenia gravis on 11/08/2022 (not FDA approved for the orphan indication), and the company announced Regenerative Medicine Advanced Therapy designation for MG on May 22, 2024. A Rare Pediatric Disease Designation for juvenile dermatomyositis (JDM) was granted in September 2024; the company states that approval in JDM may qualify it for a priority review voucher.
- Special Protocol Assessment: On January 27, 2025, the company announced written agreement from the FDA under the Special Protocol Assessment process on the overall design of the phase 3 AURORA trial, which the company states the FDA determined acceptable to support a future biologics license application (BLA) in MG, subject to the outcome of the trial.
- Earlier development: The company has completed a phase 1/2 trial in MG with phase 1b, phase 2a, and phase 2b portions; phase 2a results were published in the Lancet Neurology in July 2023, phase 2b results were presented in December 2024, and 12-month data were reported in April 2025 and published in Nature Medicine in January 2026. As of December 31, 2025, Descartes-08 had been administered to over 100 patients with MG, multiple myeloma, and other diseases.
- AURORA status: The first participant was enrolled in May 2025 (registry actual study start 2025-05-06). The company describes approximately 100 participants with AChR antibody-positive MG; the registry record last updated 2026-09-01 lists actual enrollment of 128, a status of active, not recruiting, estimated primary completion on 2026-12-30, and estimated study completion on 2027-09-30. The company expects topline data in the first quarter of 2027 and plans a BLA filing in mid-2027, and states that it has expanded its medical affairs and commercial teams for launch readiness.
- Financing: Cash, cash equivalents, and restricted cash were $124.7 million as of September 30, 2026, including the initial $50 million tranche of non-dilutive financing from K2 HealthVentures and $22.8 million raised year to date through the at-the-market program; the company expects these resources to support planned operations, including completion of AURORA, into 2028. The term loan facility provides up to $150.0 million in four tranches, of which $50.0 million had been borrowed as of September 30, 2026, and requires a minimum trailing three-month net product revenue of $40.0 million beginning on January 1, 2029. The accumulated deficit was $857.3 million, and approximately $75.5 million remained available under the at-the-market program. In its full year 2025 results (2026), the company had projected that $126.9 million as of December 31, 2025, would support operations into mid-2027.
- Other indications: The phase 2 TRITON trial in moderate to severe multi-refractory dermatomyositis and antisynthetase syndrome and the phase 1/2 HELIOS trial in children and young adults with autoimmune diseases, including JDM, are ongoing, with data from both expected in the first half of 2027. After topline data from a phase 2 trial in systemic lupus erythematosus in November 2025, the company decided to no longer pursue development in that indication.
Regulatory status: Submission planned; BLA planned for mid-2027
Launch
No evidence found.
Launch readiness: expanded medical affairs and commercial teams
AURORA topline data and BLA timing: first quarter of 2027 and mid-2027
Orphan Drug Designation for myasthenia gravis: designated November 2022
| Field | Quoted record |
|---|---|
| Generic name | “autologous T-cells expressing a chimeric antigen receptor directed against B-Cell maturation antigen” |
| Date designated | “11/08/2022” |
| Orphan designation | “Treatment of Myasthenia Gravis” |
| Orphan designation status | “Designated” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
| Sponsor | “Cartesian Therapeutics, Inc.” |